All authors made a significant contribution to the work reported, whether that is in the conception, study design, execution, acquisition of data, analysis and interpretation, or in all these areas. This study was supported by National Key Clinical Specialty Construction Project (Clinical Pharmacy) and High-Level Clinical Key Specialty (Clinical Pharmacy) in Guangdong Province. In addition, although liraglutide 3.0mg was less effective than Semaglutide 2.4mg, serious adverse events were still the most elevated. The results of the inconsistency test between the overall, local and closed-loop included in the study and heterogeneity showed that there was no statistically significant inconsistency (P ≥ 0.05 or CI_95 including 0) for each outcome indicator, the final result indicated that the consistency test results of the network are reliable. How Fast Does Semaglutide Work? Timeline and Results Understanding how much weight you can lose on semaglutide requires us to look at the data from various studies. For instance, participants in these studies lost an average of 15% of their body weight over a period of 68 weeks. By improving insulin sensitivity and reducing post-meal blood sugar spikes, semaglutide creates a supportive environment for weight loss. This dual action not only aids in weight loss but also helps stabilize blood sugar levels, which is particularly beneficial for individuals with type 2 diabetes. Let’s embark on this journey together and discover how semaglutide can help you achieve your weight loss goals. This is mirrored by similar analyses carried out on trials with other GLP‐1RAs. GI AEs were generally reported at higher rates with semaglutide than with comparators, and higher rates were observed in the subgroups with comparatively lower, rather than higher, baseline BMI (Table 2). Weight loss was generally more pronounced in subjects who experienced nausea or vomiting compared with those who did not experience such events. This effect was more marked with semaglutide 1.0 mg than with 0.5 mg. However, a consultation with a healthcare provider is necessary to determine eligibility.The corresponding weight change values for comparator treatments were −2.7 to +2.2 kg and −1.8 to +1.1 kg for subjects with or without nausea and/or vomiting, respectively (Figure 1B).In vitro studies have shown a low potential for semaglutide to affect CYP enzymes orinhibit drug transporters.Among 25 individuals who completed six-month semaglutide treatment, 16 patients received 1 mg, and the remaining nine individuals received 2 mg semaglutide dose.When that didn't work, Schorr said she reached out for professional help and saw a nurse practitioner who helps patients with weight loss.In the ever-evolving landscape of weight-loss medications, semaglutide has emerged as a groundbreaking option.Further research is needed to address several aspects of chronic semaglutide use for weight management, such as the durability of semaglutide-induced weight loss beyond two years , the optimal duration of treatment, and strategies to prevent or, at least, ameliorate weight regain occurring after semaglutide discontinuation 8,28.They can offer advice, adjust your treatment plan if necessary, and provide encouragement. Third, this study included a small number of patients, not allowing subgroup analysis in order to determine differences in semaglutide response according to individual demographic characteristics and metabolic variables. In total, identifying predictors for the effectiveness of semaglutide is essential in order to optimize therapeutic benefits in the management of obesity. In light of the bidirectional link between psychiatric disease and obesity, the weight outcomes of semaglutide in this context need to be studied . Regular follow-up appointments with your healthcare provider are crucial to monitor your progress and adjust the treatment plan as needed. In rare cases, semaglutide can cause more serious side effects, such as pancreatitis or kidney problems. Before you start using semaglutide, it’s important to have a thorough discussion with your healthcare provider. Patients should set realistic expectations for their weight loss journey, understanding that sustainable progress takes time and consistent effort. Weight loss success with semaglutide depends on realistic goals and consistent adherence to healthy lifestyle habits. ” While results vary, most patients notice changes in appetite and weight within the initial weeks. Later, in 2021, it was approved for weight loss under the brand name Wegovy®. Semaglutide was first approved by the FDA in 2017 for the treatment of type 2 diabetes under the brand name Ozempic®. The U.S. Food and Drug Administration (FDA) is the government agency responsible for approving medications for use. This means it helps control blood sugar levels and reduces appetite, leading to weight loss. When you take semaglutide, it works in your body just like the natural GLP-1 hormone. This study has included data about a wide range of metabolic parameters and the presence of comorbidities, while all weight measurements were undertaken on the same calibrated scale, minimizing any bias potentially arising from patient-reported weight or using different scales. In the future, the availability of numerous potent AOMs could usher in an era of precision medicine with the application of personalized treatment strategies, based on predictive models, encompassing age, gender, different obesity phenotypes, coexisting complications, genotype, and predictors of response to each treatment modality . In view of the substantial budgetary effects, negotiating the price of new-generation AOMs may be needed to address health inequities across different categories of socioeconomic status, as well as ensure their affordability and equitable patient access. The final result shows that the more weight loss, the greater the incidence of adverse events. In terms of hypoglycemic events, compared with placebo and semaglutide 1.0mg, except for semaglutide 2.4mg, which was significantly different, other pairwise comparisons had no statistical significance. This result shows that semaglutide 2.4mg has a complete weight loss and decreased HbA1c advantage. No cases of pancreatitis or gallbladder-related disease were recorded in this cohort in line with another real-world study , while STEP trials reported an increased likelihood for cholelithiasis at a rate of 0.8%-3.5% 7-10,12. The discontinuation rate in this study was low at 2.5%, similar to the 2.9% reported in another real-world study and lower than 5.9%-7.7% in STEP trials 7-9, but this difference might be explained by the longer follow-up period in RCTs. This real-world study showed an early improvement in glycemic markers, confirming the glucose-lowering effect reported in STEP studies 7-9. Month 4–6: Significant Weight Loss Phase Significant weight loss and glycemic control can be observed after several months of consistent use.In terms of binding of outcome assessment, seven studies did not mention being rated as unclear risk of bias.Forty-eight weeks after randomization, participants assigned to remain on semaglutide lost an additional 7.1 kg, resulting in a net 17.4% reduction in baseline weight as measured from the start of the run-in.Noteworthy, three individuals, all females with active major depressive disorder, increased their body weight during the period of semaglutide treatment.Effects of once-weekly semaglutide on appetite, energy intake, control of eating, food preference and body weight in subjects with obesity.The present analysis suggests that the contribution of nausea or vomiting to the overall semaglutide‐induced weight loss is very minor, negating these events as drivers of this weight loss and indicating that other primary contributors are responsible.In East Asian countries, the BMI threshold for obesity is ≥28.0 kg/m2 and for overweight is ≥24.0 kg/m2.18 In India, the BMI threshold for obesity is ≥25.0 kg/m2 and for overweight is ≥23.0 kg/m2.19 The decision to begin anti-obesity medications should be personalized, considering the benefits and risks of all treatment options. However, three retrospective real-world studies support the effectiveness and good safety profile of semaglutide for the treatment of weight recurrence after bariatric surgery, as evidenced by a mean 6-month body weight reduction of 9.8–10.3% (44–46). In addition, a new generation of studies should recognize distinct obesity phenotypes and evaluate the use of semaglutide for weight management in patient subgroups with different main comorbidities with primary end points other than weight, for example, the progression of liver steatohepatitis or the regression of liver fibrosis . Further research is needed to address several aspects of chronic semaglutide use for weight management, such as the durability of semaglutide-induced weight loss beyond two years , the optimal duration of treatment, and strategies to prevent or, at least, ameliorate weight regain occurring after semaglutide discontinuation 8,28. Due to its substantial and durable weight loss effect, semaglutide may herald a new era in the management of obesity, using percentage weight loss as a biomarker and applying a treat-to-target approach, in line with other chronic diseases, to prevent and treat weight-related complications . Semaglutide has been shown to increase energy expenditure and promote fat burning, leading to reductions in body weight and improvements in body composition. By suppressing the release of glucagon, semaglutide helps to lower blood sugar levels in individuals with diabetes. It works through a different mechanism than diet and exercise alone, making it valuable for people with hormonal or metabolic factors contributing to weight gain. Research indicates that some weight regain is common when treatment stops. By the end of the second month, many patients report noticeable weight loss. In the first eight weeks, the body adjusts to semaglutide’s effects. During the initial weeks of semaglutide treatment, patients typically experience reduced appetite and improved blood sugar control. While there are potential risks, the benefits of sustained weight loss and improved metabolic health are significant.I’ve tried fasting, exercising, and cutting calories but no matter what I did, the weight would not come off.Twenty-one (91.30%) studies were included, 6 (26.08%) studies were included that reported the decreased HbA1c (%), but the liraglutide 3.0mg was not reported, 18 (78.26%) studies reported the total adverse events and serious adverse events, 16 (69.56%) studies reported the hypoglycemic events.This reduction, combined with other lifestyle changes, supports sustained weight loss over time.Some people may feel side effects like nausea.We encourage patients to work closely with their healthcare providers to find the right dosage that balances efficacy with tolerability.In individuals treated with antidepressants, semaglutide seems to retain its efficacy, as suggested by a post hoc exploratory analysis of STEP trials reporting a semaglutide-induced clinically meaningful weight loss, regardless of baseline antidepressant use (52). This is true for people who use semaglutide. The process is something many people can do, and it helps both health and happiness. All of these themes show that semaglutide is not just about changing the body. This makes it feel like something anyone can use for weight management. Stories from relationship experts and busy professionals help all people connect with the medication. Further evidence is provided by Wilding et al, who examined weight change 52 weeks after medication withdrawal in a subset of 327 participants from the STEP 1 trial.47 Those originally treated by semaglutide regained 11.6 percentage points of their prior 17.3% reduction in baseline weight, while placebo-treated participants regained 1.9 percentage points of their prior 2.0% loss. Participants who received IBT combined with semaglutide 2.4 mg lost 16.0% of body weight at week 68 and achieved significantly greater improvements in multiple measures of cardiometabolic risk than the placebo-treated group. Thus, the 2.4 mg dose significantly increased weight loss, compared to 1.0 mg, the latter which was originally approved for the treatment of type 2 diabetes. All English-language articlesevaluating the efficacy and safety of semaglutide 2.4 mg for weight loss in humanswere included.While semaglutide can be highly effective, several factors can influence the amount of weight loss you may experience.Having a support system can make a significant difference in your weight loss journey.The timing of semaglutide’s effects is a common question among patients at Sanctuary Medical Aesthetic Center in Boca Raton and Fort Lauderdale.The increase in heart rate with semaglutide is especially important to consider for patients with heart failure and other cardiac conditions, and the safety of semaglutide in this population is unclear.However, some patients may be “non-responsive” to semaglutide, which using CMS guidelines is considered aWithin the broader GLP-1RA medication class, differences exist in drug structure, efficacy, and adverse events. As shown in STEP 2, semaglutide at a higher dose of 2.4 mg produces larger weight losses than the 1.0 mg dose approved for type 2 diabetes.39 Special considerations are needed when prescribing semaglutide in patients with type 2 diabetes. In pooled analyses of STEP trials 1–3, the most common adverse reactions leading to discontinuation in semaglutide versus placebo were gastrointestinal effects (4.3% in semaglutide vs 0.7% in placebo) with most discontinuations occurring in the dose-escalation period.74 If patients do not tolerate a dose during dose escalation due to gastrointestinal side effects, delaying dose escalation for 4 weeks may help to mitigate symptoms. In STEP 1, discontinuation of study medication due to adverse events was reported in 7.0% of participants on semaglutide and 3.1% of participants on placebo. In a weight loss maintenance trial with liraglutide 3.0 mg/day, the effect of the medication on increasing heart rate was attenuated when liraglutide was combined with a moderate-to-vigorous-intensity exercise program.77 Encouraging moderate-to-vigorous-intensity exercise combined with semaglutide may help to mitigate increases in heart rate and improve cardiorespiratory fitness, but studies are needed to examine the efficacy of this strategy. The medication also slows down stomach emptying, which slows down the absorption of calories and may contribute to the feeling of fullness, he added. Semaglutide "works by making people not hungry,” Dr. Leigh Perreault, an endocrinologist at UCHealth in Denver, Colorado, previously told TODAY.com. To reduce nausea while on semaglutide, registered dietitian Emily Rubin recommends skipping hot, fried or greasy food; and avoiding eating or cooking strong-smelling food. Schwartz, a sex and relationship expert, says her weight problems began in her late 30s when she simply began overeating. She lost about 30 pounds, but has regained 5 pounds back and her weight has stayed steady at that number. Here are patients’ experiences with Ozempic and Wegovy, and their before-and-after photos. Novo Nordisk says it supports a health care system that ensures patient access and affordability. Dr. Chao reports grants from WW International Co and Eli Lilly and Co, outside the submitted work. However, the use of an injectable can be a barrier to initiation and adherence due to concerns about self-administering a medication, convenience, and social acceptance. More gradual titration of semaglutide or down-titrating insulin could help mitigate rapid decreases in glucose concentrations and reduce the risk of diabetic retinopathy worsening, though further research is needed. Ongoing surveillance will be necessary to examine for additional and long-term adverse events. In most cases, gastrointestinal events were mild to moderate and had a short duration of less than four weeks. Three months following semaglutide initiation, the administered dose was 1 mg for all participants. 8Psychiatric weight-related conditions included depression, generalized anxiety disorder, and bipolar disorder or schizophrenia Other common comorbidities were MAFLD, reproductive abnormalities, psychiatric disorders, and obstructive sleep apnea, with 32 out of 40 individuals (80%) having two or more weight-related medical conditions. In total, 17 out of 40 patients (42.5%) combined the presence of at least three criteria, which constituted the diagnosis of metabolic syndrome according to the National Cholesterol Education Program (NCEP) Adult Treatment Plan III (ATP III) definition . All patients were of White Greek ethnic origin, mostly females (28/40 or 70%), with a median age of 47, ranging from 23 to 65 years old. Out of 40 patients, five individuals had undergone bariatric surgery in the past, including gastric banding in four cases and sleeve gastrectomy in one case. Information was also collected about the presence of various comorbidities according to past medical history, medication use, and available laboratory and imaging tests. For each individual, data were recorded at the baseline and in three-month intervals following semaglutide initiation about demographic parameters, anthropometric characteristics, and a wide range of laboratory parameters. All individuals received counselling sessions about nutrition and regular exercise at the time of semaglutide initiation and every 12 weeks thereafter by an endocrinologist, following the principles of motivational interviewing. Monitoring Progress: How to Track Your Weight Loss with Semaglutide Once-weekly semaglutide in adults with overweight or obesity. A new paradigm for treating to target with second-generation obesity medications. Answering these questions will determine the extent of semaglutide use as part of the rapidly expanding armamentarium and facilitate personalised treatment of obesity. Semaglutide may herald a new era in the management of obesity, introducing widespread use of pharmacotherapy to meet a large unmet clinical need. Given the nature of obesity as a chronic, relapsing, progressive disease process, studies with long follow-up in combination with pharmacovigilance activities employing databases are warranted to ensure long-term safety of semaglutide and any other AOMs. She posts lots of before and after shots so people can see what a drastic difference the drug has made. "Embracing the process, one step at a time," she says. It offers them more hope and support on their path to better health. Your progress will be better when you keep up with weekly semaglutide injections, improve your eating habits, and add some form of physical activity. The observation in these individuals was the co-occurrence of semaglutide administration and mental health deterioration, while most of those were not on psychotropic medications related to significant weight gain. This study showed the marked variability of response to semaglutide, confirming the observation in STEP trials 7-9 that a proportion of individuals do not achieve significant weight loss for unknown reasons . Another real-world study has demonstrated clinically relevant weight loss induced by low semaglutide maintenance doses, reporting a mean six-month weight loss of 9.2% in individuals receiving long-term semaglutide doses of ≤1 mg compared to 12.1% in those receiving higher doses . These weight loss outcomes are comparable with a three-month percentage weight loss of 6%-6.5% and six-month of 10.6%-12% reported in STEP 1 and STEP 4 trials 7,8, suggesting that semaglutide achieves a similar effect in routine clinical practice with that observed in RCTs. Semaglutide injections for weight loss: an overview You will likely experience a gradual and steady decline in body weight during this period. Most weight loss will typically occur within the first 4 to 5 months. Consult with healthcare professionals to determine if this treatment aligns with your goals, paving the way for a healthier future. Common Side Effects and How to Manage Them It’s essential to continue working with your healthcare provider to assess your progress and determine the best course of action for your weight loss journey. However, it’s important to remember that weight loss is a multifaceted process influenced by medication, lifestyle changes, and individual variability. In summary, semaglutide presents a promising option for individuals seeking effective weight management solutions. Our personalized assessment quiz can help you determine if semaglutide is the right fit for your weight loss journey. Another serious limitation is the exclusion of patients who did not reach 3 months of follow-up, which might have resulted in an overestimation of the association of semaglutide with body weight. In addition, the weight loss data of semaglutide use might be more representative of day-to-day clinical practice, including a more heterogenous patient population, compared with RCTs. Similar to our reported results, gastrointestinal symptoms, particularly nausea, are the most commonly reported adverse effects with semaglutide.18 We also report a significant number of patients with fatigue, which was not reported in previous studies.18 By being proactive and exploring different financial assistance options, you can make this effective weight loss treatment more accessible. While there are potential risks, the benefits of sustained weight loss and improved metabolic health are significant. This shows that semaglutide can help with significant weight loss over time. When we share these real stories, we help more people see which treatments work and how they can help.Finally, concerns about the possible association of semaglutide-induced weight loss with sarcopenia and the loss of bone density should be addressed, and if needed, strategies should be developed to ameliorate these unwanted effects.This effect was more marked with semaglutide 1.0 mg than with 0.5 mg.There you have it, ten success stories from taking semaglutide that should be enough for anyone that is curious about taking semaglutide to ask their doctor about it.After three months of semaglutide administration, the median (IQR) weight loss was 7 (5.3) kg, equivalent to 6.6% (5.5%) percentage weight loss.Wegovy is specifically approved for weight loss for people with obesity or who are overweight.Semaglutide has emerged as a groundbreaking treatment for weight loss and blood sugar control in individuals struggling with obesity and type 2 diabetes.Nevertheless, these data are consistent with infusion studies with native GLP‐1 in healthy/normal weight and obese individuals, which suggest that the observed reduction in energy intake and appetite38 is not a consequence of nausea.39 How Much Weight Do You Lose on Semaglutide? Insights into Your Weight Loss Journey However, weight loss surgery can provide faster and more dramatic results, especially for those with severe obesity. Individuals undergoing this treatment may also have to make lifestyle adjustments to support their weight loss journey. It’s crucial to discuss these potential side effects with your healthcare provider before starting treatment. Many insurance plans do cover semaglutide, but the extent of coverage can vary.In view of the potential widespread use of semaglutide, cost-effectiveness studies are of paramount importance, as well as head-to-head studies with other AOMs.In addition, we collected information on any adverse effects experienced after the initiation of semaglutide treatment.Additionally, losing weight and improving metabolic health can enhance quality of life.Before commencing Semaglutide treatment, consult with healthcare professionals to ensure that it aligns with your weight loss goals and overall well-being.In our study, 77 patients (44.0%) received the highest current doses of subcutaneous semaglutide (1.7 and 2.4 mg), while 98 (56.0%) received lower doses (0.25, 0.5, and 1 mg).Is semaglutide (SGT) effective for weight loss?8Psychiatric weight-related conditions included depression, generalized anxiety disorder, and bipolar disorder or schizophreniaMonitoring your progress is a key part of the semaglutide journey. Hypoglycemic Events This is something to be aware of because you can lose muscle mass if you do not eat the proper foods while you are on this treatment. If you are a candidate, we will start you on a treatment plan that will involve an injection once a week. Every patient has to complete a medical history, blood work and meet with our nurse Practitioner to make sure they are a good candidate for the treatment. My goal is to maintain this weight for the next three months. I am now in the process of tapering off the medication. Results can vary, but many patients start to see weight loss and improvements in blood sugar levels within a few weeks of starting semaglutide.The hospital worker in Philadelphia, Pennsylvania, says she would sometimes force herself to eat when she was taking Ozempic because of the side effects.Semaglutide 2.4mg has an absolute advantage in weight loss and decreased HbA1c, but the incidence of total adverse events is also the highest and can cause hypoglycemia.It is unclear whether this trajectory of weight regain continues in the subsequent years and to which extent, if any, a final net weight loss is achieved.Considering the observational nature of this study, we could not compare weight loss outcomes between patients receiving semaglutide and controls.Semaglutide is a medication that has gained attention for its effectiveness in promoting weight loss.This cohort study, conducted at a referral center for weight management, retrospectively collected data on the use of semaglutide for adults with overweight or obesity between January 1, 2021, and March 15, 2022, with a follow-up of up to 6 months. Robotic surgery offers precise and minimally invasive procedures for various medical conditions, including colon cancer treatment and bariatric surgery. However, it’s important to note that adherence to the treatment regimen and lifestyle adjustments are critical for optimizing the outcomes of Semaglutide therapy. Additionally, Semaglutide offers improved glycemic control, which is beneficial for individuals with diabetes. Serious side effects are rare but may include gallbladder issues or severe gastrointestinal symptoms.Among 25 patients with six-month data, 22 (88%), 17 (68%), and eight (32%) patients exceeded 5% (5.6 kg), 10% (11.2 kg), and 15% (16.8 kg) weight loss, respectively.“(Ozempic) allowed me some space to develop a healthier relationship with food because I don’t ever remember a time when I wasn’t hungry all the time,” O’Reilly, 52, a chocolatier who lives in Seattle, told TODAY.com.Together, we can navigate the path to sustainable weight loss and improved well-being."Obesity is a chronic disease, just like diabetes, high blood pressure and high cholesterol," Aronne said.One study found people who received weekly semaglutide injections lost an average of about 15 pounds after three months and about 27 pounds after six months, which translates into about a 5-pound weight loss per month.Pregnancy is a contraindication for use of semaglutide, and semaglutide should be discontinued at least 2 months before a planned pregnancy due to the long half-life.Future research efforts should not only evaluate the potential synergistic effect of combining semaglutide with other AOMs and different lifestyle interventions but also explore its use as neoadjuvant or adjuvant therapy along with bariatric surgery. Does not increase the risk of major cardiovascular (CV) events such as heart attack, stroke, or death "The best dose is the lowest dose of the medication that works," Ashton said. "We know that the phenomenon is set in the brain to restore your weight to its heaviest level, so this is not a matter of willpower. It's not a matter of eating less and moving more," she said. By activating the GLP-1 receptors in your body, Semaglutide reduces hunger and helps you consume fewer calories, leading to weight loss over time. Semaglutide, a medication increasingly recognized for its role in weight management, offers a potential solution. Only a small component (0.07 to 0.5 kg) of the total treatment difference in weight loss was explained by nausea or vomiting. Let’s break down the costs, insurance coverage, and tips for managing treatment expenses. If you are considering using semaglutide for a long time, it is essential to follow some guidelines to ensure its safety and effectiveness. They may also find it easier to engage in physical activities and maintain a healthy lifestyle. Using semaglutide can help you form better eating habits.The most common problem people talk about is nausea, but there can also be bigger issues for some people.Many healthcare workers and patients are happy with these results.Like any medication, semaglutide has potential risks, especially when used for a long time.This translates to significant weight loss for many individuals, with some achieving losses exceeding 30 pounds.This can make the medication stay in the body for a longer time, leading to a longer-lasting effect.For instance, participants in these studies lost an average of 15% of their body weight over a period of 68 weeks.By understanding what to expect and how to manage potential challenges, you can embark on your semaglutide journey with confidence and clarity. These healthy habits not only support weight loss but also improve your overall health and well-being. Regularly tracking your weight and other health markers can help you see the benefits of the treatment. In this comprehensive guide, we’ve explored the journey of using semaglutide for weight loss. New medications such as tirzepatide, a “twincretin” that combines GLP-1 and glucose-dependent insulinotropic polypeptide receptor agonism, have shown weight losses of 20.9% of initial weight loss91 and even greater weight losses than semaglutide.92 Tirzepatide is being tested in the phase 3 SURMOUNT clinical trial program. These two studies suggest the possible benefits of long-term (indefinite) treatment with semaglutide (or other medications) to facilitate the maintenance of lost weight. The novel anti-obesity medication semaglutide 2.4 mg injected subcutaneously once weekly as an adjunct to a reduced-calorie diet and physical activity helps patients achieve average losses of 9.6–17.4% of initial body weight at week 68, as well as improvements in cardiometabolic and psychosocial indices. Since STEP trials excluded patients who had major depressive disorder or bipolar disorder or schizophrenia within last two years prior to study enrollment (52), prospective studies are urgently needed to evaluate semaglutide use in patients with active mental health illness. The longest available efficacy data for semaglutide as an AOM are derived from the STEP 5 trial, showing a durable, sustained, substantial weight loss over a 2-year study duration with mean reduction in body weight of 15.2% in semaglutide group compared to 2.6% in placebo group (16). Studies show that patients who discontinued semaglutide after successful weight loss regained about two-thirds of their lost weight within a year. During this period, the combined effects of weight loss, improved metabolic health and established healthy habits often create momentum that helps maintain long-term success. Doctors caution against skipping doses of GLP-1 weight-loss drugs like Wegovy because patients who discontinue the medication for a few weeks and then restart it are more likely to have side effects. Therefore, an efficacy-effectiveness gap does not exist with respect to semaglutide in weight management, supporting the generalizability of RCT findings . In almost two-thirds of the participants, substantial weight loss was produced despite being treated with 1 mg weekly, lower than the maintenance-licensed semaglutide dose of 2.4 mg weekly. With respect to the impact of semaglutide on glycemic control, three-month semaglutide treatment resulted in the median reduction of fasting glucose by 6 mg/dL from a baseline value of 99 mg/dL, while four out of 11 participants (36.3%) with HbA1c in the range of prediabetes at the baseline reverted to normal HbA1c levels. In terms of serious adverse reactions, only liraglutide 3.0 mg was significantly different compared to placebo, and others were not statistically significant. The best decreased HbA1c effect is semaglutide 2.4mg, which can get 1.48%, followed by semaglutide 1.0mg 1.36%, liraglutide 1.23%. (A) (Weight loss), (B) (decreased HbA1c), (C) (total adverse events), (D) (serious adverse events), (E) (hypoglycemic events). The control group for 3 studies (14,21,22) was non-GLP-1 hypoglycemic drugs (such as sitagliptin, glimepiride and metformin). Semaglutide-induced gastrointestinal events, albeit common, are transient, mild to moderate in severity, include gallbladder-related events, primarily cholelithiasis, and lead to drug discontinuation in 5.9–7.7% of patients (22, 23, 20, 34, 36, 56). However, prospective studies are warranted to confirm the neuropsychiatric safety of semaglutide. Besides the need for efficacy outcomes in this population, the neuropsychiatric safety of semaglutide warrants evaluation in light of postmarketing reports about suicidal thoughts and behaviours in patients receiving semaglutide. Psychiatric conditions and obesity frequently occur together and have a bidirectional relationship (49), highlighting the need to generate specific data about semaglutide use in this context. Key Points I’m a little nervous about weight regain, but I’m certainly more mindful and appreciative of my lifestyle changes. The goal is to eventually work my way off semaglutide, so my nurse practitioner recently reduced my dosage as I enter more of a maintenance mode. Aside from some lingering nausea and reduced appetite, my other side effects also subsided and I feel really good. At my peak, I was taking 1.5 mg a week, and by the end of August, I officially hit my goal weight. At week 68, participants treated by semaglutide 2.4 mg, semaglutide 1.0 mg, and placebo lost a mean of 9.6, 7.0, and 3.4% of baseline body weight, respectively. Below we summarize the published trials of semaglutide for chronic weight management which includes STEP trials 1–6, and 8. In this paper, we summarize the weight loss efficacy of semaglutide and discuss the criteria to be considered in the selection of patients who are candidates for semaglutide and special considerations related to its use in different patient populations. The United States Food and Drug Administration (FDA) has approved five medications, as adjuncts to a reduced-calorie diet and increased physical activity, for chronic weight management. As you consider semaglutide as a weight loss option, it’s essential to recognize that sustainable weight loss is a long-term commitment. If you’re considering semaglutide as part of your weight loss journey, there are several strategies you can implement to maximize your results. For example, individuals with a higher body mass index (BMI) may experience more significant weight loss compared to those with a lower BMI. Personal factors such as age, gender, genetics, and underlying health conditions can impact weight loss results. The model used to impute counterfactual values of body weight also included the interaction between treatment and each baseline variable and the interaction between any nausea or vomiting and each baseline variable.Two published trials directly compare semaglutide to liraglutide; another GLP-1receptor agonist indicated for weight loss.Secondary end points were the proportion of patients achieving weight loss of 5% or more, 10% or more, 15% or more, and 20% or more after 3 and 6 months and the percentage of weight loss for patients with or without type 2 diabetes after 3 and 6 months.Reducing body weight mitigates both diabetes‐ and CV‐related risks; a weight loss of at least 5% improves glucose, lipid and blood pressure control in overweight or obese patients with type 2 diabetes.5Semaglutide-induced gastrointestinal events, albeit common, are transient, mild to moderate in severity, include gallbladder-related events, primarily cholelithiasis, and lead to drug discontinuation in 5.9–7.7% of patients (22, 23, 20, 34, 36, 56).To reduce nausea while on semaglutide, registered dietitian Emily Rubin recommends skipping hot, fried or greasy food; and avoiding eating or cooking strong-smelling food.The American Diabetes Association (ADA) recommends an A1C goal of less than 7% for many adults with type 2 diabetes. Managing challenges on the semaglutide journey requires patience, persistence, and support. If you are struggling with any aspect of your semaglutide journey, do not hesitate to seek professional help. If side effects are severe or do not improve over time, it is important to talk to your doctor. Some people may experience nausea, vomiting, diarrhea, or constipation. A balanced diet and regular exercise are key components of a healthy lifestyle. After years of dieting and attempting every weight loss hack on the planet, semaglutide gave me an opportunity to lose weight without feeling restricted. If you wish to receive one of these medications, speak to your local healthcare provider. It is important to inform your healthcare provider about all medications and supplements you are taking to avoid potential interactions. Yes, semaglutide can interact with other medications, particularly those that affect blood sugar levels, such as insulin and oral hypoglycemics. Setting achievable goals, tracking progress, and celebrating small victories can keep patients motivated. Activities like walking, swimming, or strength training can improve metabolic health, enhance muscle tone, and support overall well-being. Patients should aim for at least 150 minutes of moderate exercise per week, as recommended by healthcare providers. These include its efficacy and safety, as well as its contraindications, potential adverse effects, management of comorbidities and drug interactions, insurance coverage and cost, and patient preferences. In this paper, we discuss considerations for the selection of individuals who are candidates for semaglutide and special considerations related to the use of this medication. Despite these average benefits, prescribers should carefully assess the suitability of patients for this medication. Semaglutide exhibited a positive effect on blood pressure, C-reactive protein, and lipid profiles, expressed more adverse effects than placebo, mainly gastrointestinal reactions. Before-and-after results show less weight, smaller dress sizes, and better fitness. Big changes in life often start with small steps. Patients see better health, and their journey can be inspiring. The primary endpoint was the change in HbA1c from baseline to end of treatment (30 or 56 weeks). In the pre‐planned analyses, the key endpoints were similar across all of the SUSTAIN 1 to 5 trials. All trials were conducted in compliance with the International Conference on Harmonization Good Clinical Practice guidelines22 and the Declaration of Helsinki.23 The protocol was approved by local ethics committees and institutional review boards. The key inclusion/exclusion criteria were similar across the SUSTAIN 1 to 5 trials. Despite the wealth of high-quality evidence, there is a paucity of real-life data limited to one cohort study . People with obesity should receive personalized care from a multidisciplinary team, including a combination of medical nutrition therapy and physical activity, supplemented by psychological and behavioral interventions. It’s also important to develop a support system, whether through family, friends, or a weight loss clinic, to maintain accountability and encouragement. Sustainable weight loss requires consistency and the gradual building of positive lifestyle habits. Incorporating physical activity into daily routines is essential for maintaining weight loss. At TrimRx, we believe that taking a proactive approach to health is vital. Whether it’s friends, family, or a professional team, surrounding yourself with people who understand your goals can provide encouragement and accountability. This early success can be encouraging and serve as a motivating factor to continue the treatment. Additionally, semaglutide slows gastric emptying, meaning food remains in the stomach longer, contributing to prolonged feelings of fullness. As a result, semaglutide can help individuals feel fuller sooner and reduce cravings, making it easier to adhere to a reduced-calorie diet. Table 1. Demographic and Clinical Characteristics. We excluded patients with a history of bariatric procedures (ie, surgical or endoscopic), taking other FDA-approved AOMs, or with an active malignant neoplasm or pregnancy. The Mayo Clinic institutional review board approved the study and waived the need for informed consent owing to its minimal-risk nature. Weekly 1.7-mg or 2.4-mg semaglutide subcutaneous injections for 3 to 6 months. Ifpatients do not tolerate a dose during escalation, clinicians should consider a4-week delay in dose escalation. Theelimination half-life of semaglutide is approximately 1 week; therefore, semaglutidewill be present for approximately 5-7 weeks after the last dose. GLP-1 is an incretin hormone with receptors present in several areas of the body,including pancreatic alpha and beta cells, the stomach, and the central nervoussystem. Gastrointestinal sideeffects were the most frequently reported side effects, including nausea,vomiting, constipation, and diarrhea. Appetite suppressants, like semaglutide, can create a challenge in getting proper nutrition leading to potential side effects. This can make the medication stay in the body for a longer time, leading to a longer-lasting effect. People with higher metabolic rates tend to process medications more quickly. However, you need to use semaglutide in conjunction with a healthy eating and exercise program to achieve lasting results.